The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Glucocorticoid use and abuse in SLE
Abstract
Glucocorticoids (GCs) are potent anti-inflammatory and immunosuppressive agents. They act by two different mechanisms: the genomic and the non-genomic pathways. The genomic pathway is considered responsible for many adverse effects of GCs, most of them are time and dose dependent. Observational studies support a relationship between GCs and damage in SLE. GCs have been associated with the development of osteoporosis, osteonecrosis, cataracts, hyperglycaemia, coronary heart disease and cognitive impairment, among others. Although no clinical trial has compared high vs low doses of GCs, some studies have shown the efficacy of medium doses in severe forms of SLE. The dose below which treatment can be considered safe has not been defined, but daily doses <7.5 mg of prednisone seem to minimize adverse effects. Combination therapy with HCQ and the judicious use of immunosuppressive drugs help to keep prednisone therapy within those limits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Genomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
Petri, M., Lakatta, C., Magder, L., & Goldman, D. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90151-1 · Cited by 323
Glucocorticoids and the risk for initiation of hypoglycemic therapy
Gurwitz, J. H. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420010131015 · Cited by 314
Kleiman, A., & Tuckermann, J. P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.009 · Cited by 165
Cited by
Furie, R., Khamashta, M., Merrill, J. T., Werth, V. P., Kalunian, K., Brohawn, P., Illei, G. G., Drappa, J., Wang, L., Yoo, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39962 · Cited by 882
Self-citationKiriakidou, M., & Ching, C. L. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202006020 · Cited by 821
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Khamashta, M., Merrill, J. T., Werth, V. P., Furie, R., Kalunian, K., Illei, G. G., Drappa, J., Wang, L., & Greth, W. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208562 · Cited by 503
Self-citationHoi, A., Igel, T., Mok, C. C., & Arnaud, L. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00398-2 · Cited by 399
Metadata
- Authors
- Ruiz-Irastorza, G., Danza, A., & Khamashta, M.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-01-23
- Volume
- 51
- Issue
- 7
- Pages
- 1145-1153
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2103509618
- Cited by
- 248
- References
- 7
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucocorticoid use and abuse in SLE. https://app.cochat.ai/papers/10.1093/rheumatology/ker410
- The paper
- Ruiz-Irastorza, G., Danza, A., & Khamashta, M. (2012). Glucocorticoid use and abuse in SLE. Rheumatology. https://doi.org/10.1093/rheumatology/ker410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.